PL354540A1 - Leki do leczenia złośliwych guzów - Google Patents

Leki do leczenia złośliwych guzów

Info

Publication number
PL354540A1
PL354540A1 PL00354540A PL35454000A PL354540A1 PL 354540 A1 PL354540 A1 PL 354540A1 PL 00354540 A PL00354540 A PL 00354540A PL 35454000 A PL35454000 A PL 35454000A PL 354540 A1 PL354540 A1 PL 354540A1
Authority
PL
Poland
Prior art keywords
drugs
treatment
malignant tumours
tumours
malignant
Prior art date
Application number
PL00354540A
Other languages
English (en)
Other versions
PL199781B1 (pl
Inventor
Gunnar Hedlund
Karl Jansson
Stig Jonsson
Anders Bjork
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Priority claimed from SE0002320A external-priority patent/SE0002320D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of PL354540A1 publication Critical patent/PL354540A1/pl
Publication of PL199781B1 publication Critical patent/PL199781B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL354540A 1999-10-25 2000-10-24 Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania PL199781B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (2)

Publication Number Publication Date
PL354540A1 true PL354540A1 (pl) 2004-01-26
PL199781B1 PL199781B1 (pl) 2008-10-31

Family

ID=31980718

Family Applications (1)

Application Number Title Priority Date Filing Date
PL354540A PL199781B1 (pl) 1999-10-25 2000-10-24 Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania

Country Status (4)

Country Link
US (1) US6395750B1 (pl)
CN (1) CN100390148C (pl)
PL (1) PL199781B1 (pl)
RS (1) RS51019B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153347A1 (de) * 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinolin-2-on-Verbindungen
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL1773816T3 (pl) * 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
EP2035001B1 (en) * 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CN104311486A (zh) * 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
MX361711B (es) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Star Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
DK2458992T3 (en) * 2009-07-30 2016-02-08 Teva Pharma Treatment of crohn's disease with laquinimod
PL2467372T3 (pl) * 2009-08-10 2017-04-28 Teva Pharmaceutical Industries Ltd. Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
NZ602510A (en) * 2010-03-03 2014-11-28 Teva Pharma Treatment of lupus nephritis using laquinimod
PE20130690A1 (es) * 2010-03-03 2013-07-07 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato
PH12012501741A1 (en) * 2010-03-03 2012-11-12 Teva Pharma Treatment of lupus arthritis using laquinimod
US8653101B2 (en) 2010-08-27 2014-02-18 Gruenenthal Gmbh Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators
ES2537615T3 (es) 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidas como moduladores de KCNQ2/3
WO2012025237A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
EP2611780A1 (en) 2010-09-01 2013-07-10 Grünenthal GmbH Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
MX2014009373A (es) 2012-02-03 2014-08-27 Teva Pharma Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea.
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
SG11201506409RA (en) 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
CN103319403B (zh) * 2013-05-10 2016-03-30 重庆理工大学 一种肿瘤血管新生抑制剂己啉酮及其制备方法和用途
CN103664777A (zh) * 2013-10-09 2014-03-26 重庆理工大学 一种美啉醇化合物、制备方法及其药物组合物和用途
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
US9956212B2 (en) * 2014-09-23 2018-05-01 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP4452946A4 (en) * 2021-12-20 2025-11-26 Univ Johns Hopkins CONNECTIONS FOR THE TREATMENT OF CANCER

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
YU23202A (sh) 2004-11-25
US6395750B1 (en) 2002-05-28
PL199781B1 (pl) 2008-10-31
CN1589264A (zh) 2005-03-02
CN100390148C (zh) 2008-05-28
RS51019B (sr) 2010-10-31

Similar Documents

Publication Publication Date Title
PL354540A1 (pl) Leki do leczenia złośliwych guzów
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
HUP0500424A3 (en) Combination therapy for the treatment of cancer
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
AU2508597A (en) Drug for the treatment of tumours
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
HUP0200805A3 (en) Improved cancer treatment with temozolomide
ZA200110436B (en) Therapeutic use of melatonin.
AU4369800A (en) Treatment of metastatic cancer through mts-1 gene
HUP0101947A3 (en) Combination for the treatment of tumors
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
HUP0200825A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
ZA200203166B (en) Treatment of cancer.
AU5552400A (en) Treatment of cancer
HU0001891D0 (en) Medicament for the treatment of migraine
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
GB9911183D0 (en) Treatment of cancers
GB9927106D0 (en) Cancer treatment
GB9908176D0 (en) Cancer treatment
GB9911346D0 (en) Treatment of cancers
GB9927005D0 (en) Treatment of cancers